Neogenomics Inc.
NEO
Get informed when a big investor buys or sells
+ FollowMarket Cap$436.3M
Close$
$-9.51
157.3% downside
Current Fair Value
157.3% downsideOvervalued by 157.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $436.30 Million |
|---|---|
| Enterprise Value | $739.13 Million |
| Dividend Yield | $0.40 (-) |
| Earnings per Share | $-4.2 |
| Beta | 1.73 |
| Outstanding Shares | 25,925,600 |
Return
| Return on Equity | -6.60% |
|---|---|
| Return on Assets | -3.84% |
| Return on Invested Capital | -3.65% |
Valuation & Multiples
| P/E Ratio | -8.56 |
|---|---|
| PEG | 8.15 |
| Price to Sales | 0.57 |
| Price to Book Ratio | 0.55 |
| Enterprise Value to Revenue | 0.96 |
| Enterprise Value to EBIT | -16.27 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.61 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$196.95 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$205.89 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0059▼ 9.69% |
|---|---|
| Total Calls | 9,164,650▲ 998.48% |
| Total Puts | 53,700▼ 37.34% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 573.61%▲ 52.17% |
|---|---|
| Total Invested | $2.27B▲ 128.40% |
| Investors Holding | 277▲ 17.00% |
ESG Score
No data
About Neogenomics Inc.
1,600 employeesNeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...